ALLMedicine™ Activated Protein C Resistance Center
Research & Reviews 77 results
https://doi.org/10.1111/jth.15199
Journal of Thrombosis and Haemostasis : JTH; Pontara E, Cattini MG et. al.
Nov 29th, 2020 - Most high-risk thrombotic antiphospholipid syndrome (APS) patients test positive for anti-β2-glycoprotein I (aβ2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Information on the influence of these antibodies on thrombin generati...
https://doi.org/10.1515/cclm-2019-1160
Clinical Chemistry and Laboratory Medicine; Favaloro EJ, Gilmore G et. al.
Mar 3rd, 2020 - Background Investigation of hemostasis is problematic when patients are on anticoagulant therapy. Rivaroxaban especially causes substantial interference, extending many clot-based tests, thereby leading to false positive or negative events. In par...
https://doi.org/10.5858/arpa.2019-0497-OA
Archives of Pathology & Laboratory Medicine; Maryamchik E, Van Cott EM
Feb 26th, 2020 - Apixaban causes a false increase in activated protein C resistance (APCR) ratios and possibly protein S activity. To investigate whether this increase can mask a diagnosis of factor V Leiden (FVL) or protein S deficiency in an actual population of...
https://doi.org/10.1111/jth.14745
Journal of Thrombosis and Haemostasis : JTH REFERENCES; Morimont L, Bouvy C et. al.
Jan 27th, 2020 - The evaluation of the activated protein C resistance (APCr) based on the endogenous thrombin potential (ETP) is recommended during the development of steroid contraceptives. Results are usually expressed as "normalized APC sensitivity ratio" (nAPC...
https://doi.org/10.1515/cclm-2019-0650
Clinical Chemistry and Laboratory Medicine; Kopytek M, Ząbczyk M et. al.
Sep 20th, 2019 - Background Direct oral anticoagulants (DOACs) may cause false results of activated protein C resistance (APC-R) ratio. DOAC-Remove, a new reagent based on activated carbon, has been designed to eliminate the interference of DOACs on coagulation as...
Clinicaltrials.gov 77 results
https://doi.org/10.1111/jth.15199
Journal of Thrombosis and Haemostasis : JTH; Pontara E, Cattini MG et. al.
Nov 29th, 2020 - Most high-risk thrombotic antiphospholipid syndrome (APS) patients test positive for anti-β2-glycoprotein I (aβ2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Information on the influence of these antibodies on thrombin generati...
https://doi.org/10.1515/cclm-2019-1160
Clinical Chemistry and Laboratory Medicine; Favaloro EJ, Gilmore G et. al.
Mar 3rd, 2020 - Background Investigation of hemostasis is problematic when patients are on anticoagulant therapy. Rivaroxaban especially causes substantial interference, extending many clot-based tests, thereby leading to false positive or negative events. In par...
https://doi.org/10.5858/arpa.2019-0497-OA
Archives of Pathology & Laboratory Medicine; Maryamchik E, Van Cott EM
Feb 26th, 2020 - Apixaban causes a false increase in activated protein C resistance (APCR) ratios and possibly protein S activity. To investigate whether this increase can mask a diagnosis of factor V Leiden (FVL) or protein S deficiency in an actual population of...
https://doi.org/10.1111/jth.14745
Journal of Thrombosis and Haemostasis : JTH REFERENCES; Morimont L, Bouvy C et. al.
Jan 27th, 2020 - The evaluation of the activated protein C resistance (APCr) based on the endogenous thrombin potential (ETP) is recommended during the development of steroid contraceptives. Results are usually expressed as "normalized APC sensitivity ratio" (nAPC...
https://doi.org/10.1515/cclm-2019-0650
Clinical Chemistry and Laboratory Medicine; Kopytek M, Ząbczyk M et. al.
Sep 20th, 2019 - Background Direct oral anticoagulants (DOACs) may cause false results of activated protein C resistance (APC-R) ratio. DOAC-Remove, a new reagent based on activated carbon, has been designed to eliminate the interference of DOACs on coagulation as...
